HOME
>
基礎医学
>
病理学
> 解明病理学　第4版

解明病理学　第4版

出版社：	医歯薬出版
著者：	青笹克之(監修) 加藤光保金井弥栄菅野祐幸(編)
発行日：	2021-11-10
分野：	基礎医学 > 病理学
ISBN：	9784263732038
電子書籍版：	2021-11-10 （第4版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

18,700 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

18,700 円(税込)

購入する

商品紹介

病理学の定本に最新知見を取り入れ，バージョンアップ！
病気の肉眼的・組織学的特徴とその成り立ちを分子レベルで詳解．
個別の疾患については，わが国の疾患実態に即して記載．
多くの簡明なシェーマを用い，病態を平易かつ明解に示すことにより，初学者でも疾患の病態生理を容易に理解できる．
主要な疾患を中心に，重要疾患は表にまとめて提示し，わかりやすく，効率的に学習できるよう編集．

目次

総論
第1章　細胞傷害と細胞・組織の反応
　第2章　炎症
　第3章　循環障害
　第4章　遺伝性疾患
　第5章　免疫
　第6章　感染症
　第7章　腫瘍
　第8章　代謝異常
　第9章　環境
　第10章　小児
　第11章　ゲノム医療と病理学
　第12章　病理学と機械学習

各論
　第1章　循環器
　第2章　呼吸器
　第3章　消化管
　第4章　肝・胆・膵
　第5章　腎
　第6章　尿路
　第7章　男性生殖器
　第8章　女性生殖器
　第9章　造血器
　第10章　皮膚
　第11章　神経・筋疾患
　第12章　乳腺
　第13章　内分泌
　第14章　縦隔・胸膜
　第15章　眼
　第16章　骨・関節・軟部組織
　第17章　口腔

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.28 掲載の参考文献

1) Choi AMK, et al. Autophagy in human health and disease. N Engl J Med. 2013;368:651-662.

2) Duffield JS, et al. Host responses in tissue repair and fibrosis. Annu Rev Pathol Mech Dis. 2013;8:241-276.

3) Kumar V, et al. Cell injury, cell death, and adaptations. In:Kumar V, et al, editors. Robbins Basic Pathology. 10th edition. Elsevier:2018. p.31-56.

4) Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370:455-465.

5) Lopez-Otin C, et al. The hallmarks of aging. Cell 2013:153:1194-1217.

6) Mitchell RN. The cell as a unit of health and disease. In:Kumar V, et al, editors. Robbins Basic Pathology. 10th edition. Elsevier;2018. p.1-29.

7) Murrow L, Debnath J. Autophagy as a stress-response and quality-control mechanism:Implications for cell injury and human disease. Annu Rev Pathol Mech Dis. 2013;8:105-137.

P.57 掲載の参考文献

1) Allen SJ, et al. Chemokine:receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787-820.

2) Appelberg R. Neutrophils and intracellular pathogens:beyond phagocytosis and killing. Trends Microbiol. 2007;15:87-92.

3) Blobe GC, et al. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-1358.

4) Castanheira FVS, Kubes P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood 2019;133;2178-2185.

5) Crusz, SM, Balkwill, FR. Inflammation and cancer:advances and new agents. Nat Rev Clin Oncol. 2015;12:584-596.

6) Dejana E. The transcellular railway:insights into leukocyte diapedesis. Nat Cell Biol. 2006;8:105-107.

7) Furman D, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25:1822-1832.

8) Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.

9) Greten ER, et al. Inflammation and Cancer:Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27-41.

10) Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-852.

11) Kaplan MJ, Radic M. Neutrophil extracellular traps:double-edged swords of innate immunity. J Immunol. 2012;189:2689-2695.

12) Karin M, Greten FR. NF-kappaB:linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759.

13) Klose CSN, Artis D. Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity. Cell Res. 2000;30:475-491.

14) Levy DE, Darnell JE Jr. Stats:transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651-662.

15) Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449:819-826.

16) Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000;343:338-344.

17) Petri B, Bixel MG. Molecular events during leukocyte diapedesis. FEBS J. 2006;273:4399-4407.

18) Pikarsky E, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461-466.

19) Rosales C. Front Physiol. Neutrophil:A cell with many roles in inflammation or several cell types? 2018;20:113.

20) Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-1713.

21) Savill J, et al. A blast from the past:clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965-975.

22) Serhan CN. Resolution phase of inflammation:novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101-137.

23) Takeda K, et al. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.

24) Underhill DM, Ozinsky A. Phagocytosis of microbes:complexity in action. Annu Rev Immunol. 2002;20:825-852.

25) Weber C, et al. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol. 2007;7:467-477.

26) Yoshimura A, et al. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454-465.

27) Zhong Z, et al. Autophagy, inflammation, and immunity:a troika governing cancer and its treatment. Cell. 2016;166:288-298.

P.78 掲載の参考文献

1) Robbins and Cotran Pathologic Basis of Disease, 9th ed.

P.93 掲載の参考文献

1) 渡邉淳. 診療・研究にダイレクトにつながる遺伝医学. 羊土社;2017.

2) 福嶋義光監訳. トンプソン&トンプソン遺伝医学. 第2版. 2017.

3) 日本医学会・全国遺伝子医療部門連絡会議・日本人類遺伝学会・日本遺伝カウンセリング学会. 医学部卒前遺伝医学教育モデルカリキュラム:2013 https://jshg.jp/wp-content/uploads/2017/08/1c9ddec33431549ca74cbf63ceb4ccbf.pdf

4) 日本医学会. 医療における遺伝学的検査・診断に関するガイドライン:2011 http://jams.med.or.jp/guideline/genetics-diagnosis.html

5) 個人情報保護委員会, 厚生労働省. 医療・介護関係事業者における個人情報の適切な取扱いのためのガイダンス:2017 https://www.mhlw.go.jp/content/000681800.pdf

6) Hoskinson DC, Dubuc AM, Mason-Suares H. The current state of clinical interpretation of sequence variants. Curr Opin Genet Dev. 2017;42:33-39.

P.140 掲載の参考文献

1) Murphy K, Weaver C. Janeway's Immunobiology, 9th ed. Garland Science;2017.

2) Abbas AK, Lichtman AHH, Pillai S. Cellular and Molecular Immunology, 8th ed. Saunders;2014.

3) Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol. Rev. 2013;255:165-181.

4) Shimaoka M, ed. Integrin and Cell Adhesion Molecules. Methods and Protocols. Methods in Molecular Biology 757, Humana Press;2012.

5) Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nature Rev Immunol. 2009;9:153-161.

6) Masopust D, Schenkel KM. The integration of T cell migration, differentiation and function. Nature Rev Immunol. 2013;13:309-319.

7) Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nature Rev Immunol. 2013;13:159-175.

8) Guilliams M, et al. Dendritic cells, monocytes and macrophages:a unified nomenclature based on ontogeny Na-ture Rev Immunol. 2014;14:571-578.

9) 塩沢俊一. 膠原病学改訂第6版. 丸善出版;2015.

P.174 掲載の参考文献

1) Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328.

2) Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486.

3) Violari A, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233.

4) Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917.

5) Sabio JM, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;345:376.

6) Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175.

7) Jasmer RM, et al. Latent tuberculosis infection. N Engl J Med. 2002;347:1860.

8) Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med . 2000;343:1703.

9) Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med. 1998;339:1994.

P.204 掲載の参考文献

1) 国立がん研究センターがん登録・統計. http://ganjoho.jp/reg_stat/statistics/stat/index.html

2) Hanahan D, Weinberg RA. Hallmarks of cancer:The next generation. Cell. 2011;144:646-674.

3) Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-2823.

4) Clevers H. The cancer stem cell:premises, promises and challenges. Nat Med. 2011;17:313-319.

5) Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56-61.

6) Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med. 2008;359:722-734.

7) Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107-1120.

8) Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91-95.

9) Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495-501.

10) Nik-Zainal S, Davis H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47-54.

11) The Cancer Genome Atlas Network. Comprehensive moleculer characterization of human colon and rectal cancer. Nature. 2012;487:330-337.

P.225 掲載の参考文献

1) Robert KM, David AB, Kathleen MB, et al. Harper's Illustrated Biochemistry, 31e, a LANGE medical book, Mc-Graw-Hill Companies;2018.

2) 糖尿病学会編. 糖尿病治療ガイド2020-2021. 文光堂;2012.

3) Scheja L, Heeren J, Shaw J. The endocrine function of adipose tissues in health and cardiometabolic disease. Nature Reviews, Endocrinology. 2019;15:507-524.

4) Picken MM. The pathology of amyloidosis in classification:a review. Acta Haematologica. 2020;143:322-334.

5) Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389:1238-1252.

P.239 掲載の参考文献

1) Doll R, Peto R. The causes of cancer:quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191-1308.

2) Beryllium, cadmium, mercury, and exposures in the glass manufacturing industry. IARC Monogr Eval Carcinog Risks Hum. 58 (1993) 1-415.

3) Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 83 (2004) 1-1438.

4) Inorganic and organic lead compounds. IARC Monogr Eval Carcinog Risks Hum. 87 (2006) 1-471.

5) Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog Risks Hum. 96 (2010) 3-1383.

6) Chemical agents and related occupations. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 9-562.

7) Pharmaceuticals. Volume 100 A. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 1-401.

8) Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 1-441.

9) Radiation. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 7-303.

10) Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 11-465.

11) Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 100 (2012) 1-538.

12) International Agency for Research on Cancer, World Health Organization, World cancer report 2014, Stewart BW, Wild C, eds. p.134-142.

P.264 掲載の参考文献

1) Maitra A. Chapter 7. Genetic and Pediatric Diseases. In:Kumar V, Abbas AK, Aster JC, editors. Robbins Basic Pathology. 10th ed. Elsevier Saunders;2017. p243-298.

2) 財団法人厚生統計協会. 国民衛生の動向2020/2021. 厚生の示標財団法人厚生統計協会;2020. p.406.

3) Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338:1128-1137.

4) Latchman DS. Transcription-factor mutations and disease. N Engl J Med. 1996;334:28-33.

5) Lim HT, Kim DH, Kim H. PAX6 aniridia syndrome:clinics, genetics, and therapeutics. Curr Opin Ophthalmol. 2017;28:436-447.

6) Lee RT, Zhao Z, Ingham PW. Hedgehog signalling. Development. 2016;143:367-372.

7) Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344:581-590.

8) Davies JC, Alton EW, Bush A. Cystic fibrosis. Brit Med J. 2007;335:1255-1259.

9) Fonseca C, Bicker J, Alves G, Falcao A, Fortuna A. Cystic fibrosis:physiopathology and the latest pharmacological treatments. Pharmacol Res. 2020:105267.

10) Rubens D, Sarnat HB. Sudden infant death syndrome:an update and new perspectives of etiology. Handb Clin Neurol. 2013;112:867-874.

11) 国立がん研究センターがん情報サービス小児AYA世代のがん. https://ganjoho.jp/reg_stat/statistics/stat/child_aya.html

12) Maris JM. Recent Advances in Neuroblastoma. N Engl J Med. 2010;362:2202-2211.

13) Mallepalli S, Gupta MK, Vadde R. Neuroblastoma:An Updated Review on Biology and Treatment. Curr Drug Me-tab. 2019;20:1014-1022.

14) Irtan S, Ehrlich PF, Pritchard-Jones K. Wilms tumor:"State-of-the-art" update, 2016. Semin Pediatr Surg. 2016;25:250-256.

15) Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor:A review. J Neurosci Res. 2019;97:29-44.

P.278 掲載の参考文献

1) Manolio TA, Rowley R, Williams MS, Roden D, Ginsburg GS, Bult C, Chisholm RL, Deverka PA, McLeod H, Mensah GA, Relling MV, Rodriguez LL, Tamburro C, Green ED. Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet. 2019;394:511-520.

2) Wise AL, Manolio TA, Mensah GA, Peterson JF, Roden DM, Tamburro C, Williams MS, Green ED. Genomic medicine for undiagnosed diseases. Lancet. 2019;394:533-540.

3) Hulsen T, Jamuar SS, Moody AR, Karnes JH, Varga O, Hedensted S, Spreafico R, Hafler DA, McKinney EF. From big data to precision medicine. Front. Med. 2019;6:34.

4) Karki R, Pandya D, Elston RC, Ferlini C. Defining "mutation" and "polymorphism" in the era of personal genomics. BMC Med Genomics. 2015;8:37.

5) Samorodnitsky E, Jewell BM, Hagopian R, Miya J, Wing MR, Lyon E, Damodaran S, Bhatt D, Reeser JW, Datta J, Roychowdhury S. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum Mutat. 2015;36:903-914.

6) Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817-1824.

7) Hicks S, Wheeler DA, Plon SE, Kimme M. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum. Mutat. 2011;32:661-668.

8) Sim N-L, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server:predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452-W457.

9) Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.

10) Sunami K, Ichikawa H, Kubo K, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting:A hospital-based study. Cancer Sci. 2019;110:1480-1490.

11) Vears DF, Niemiec E, Howard HC, Borry P. Analysis of VUS reporting, variant reinterpretation and recontact policies in clinical genomic sequencing consent forms. Eur J Hum Genet. 2018;26:1743-1751.

12) Thomas DM, James PA, Ballinger ML. Clinical implications of genomics for cancer risk genetics. Lancet Oncol. 2015;16:e303-308.

13) Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG;American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findsings in clinical exome and genome sequencing. Genet Med. 2013;15:565-574.

14) 厚生労働省. がんゲノム医療中核拠点病院などの指定要件に関する報告書. https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000190028.pdf.2017.

15) Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, Korn WM, Shields AF, Worrilow WM, Kim ES, Lenz HJ, Marshall JL, Hall MJ. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020. doi:10. 1002/ijc. 33115.

16) 一般社団法人日本病理学会. ゲノム研究用・診療用病理組織検体取扱い規程. 2019年3月1日発行. 羊土社.

17) Kanai Y, Nishihara H, Miyagi Y, Tsuruyama T, Taguchi K, Katoh H, Takeuchi T, Gotoh M, Kuramoto J, Arai E, Ojima H, Shibuya A, Yoshida T, Akahane T, Kasajima R, Morita KI, Inazawa J, Sasaki T, Fukayama M, Oda Y. The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research:Standard operating procedures based on empirical analyses. Pathol Int. 2018;68:63-90.

18) Mano H. ALKoma:a cancer subtype with a shared target. Cancer Discov. 2012;2:495-502.

19) Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.

20) Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of tumors of the central nervous system:a summary. Acta Neuropathol. 2016;131:803-820.

P.288 掲載の参考文献

1) 人工知能学会. 人工知能の話題. https://wwwai-gakkaiorjp/whatsai/AItopics5html.

2) Rosenblatt F. The perceptron:a probabilistic model for information storage and organization in the brain. Psychol Rev. 1958;65(6):386-408.

3) David E. Rumelhart GEH, Ronald J. Williams Learning representations by back-propagating errors. Nature. 1986;323:533-536.

4) Hinton GE, Salakhutdinov RR. Reducing the dimensionality of data with neural networks. Science. 2006;313(5786):504-507.

5) Simon P. Too Big to Ignore:The Business Case for Big Data:Wiley;2013.

6) Mitchell TM. Machine Learning:McGraw-Hill Educa-tion;1997.

7) Silver D, Huang A, Maddison CJ, Guez A, Sifre L, van den Driessche G, et al. Mastering the game of Go with deep neural networks and tree search. Nature . 2016;529(7587):484-489.

8) Krizhevsky A, Sutskever I, Hinton GE. ImageNet Classification with Deep Convolutional Neural Networks. Commun Acm. 2017;60(6):84-90.

9) Yamamoto Y, Tsuzuki T, Akatsuka J, Ueki M, Morikawa H, Numata Y, et al. Automated acquisition of explainable knowledge from unannotated histopathology images. Nat Commun. 2019;10(1):5642.

10) Campanella G, Hanna MG, Geneslaw L, Miraflor A, Werneck Krauss Silva V, Busam KJ, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med . 2019;25(8):1301-1309.

11) R. Girshick JD, T. Darrell and J. Malik. Rich Feature Hierarchies for Accurate Object Detection and Semantic Segmentation. 2014 IEEE Conference on Computer Vision and Pattern Recognition. 2014:580-587.

12) J. Redmon SD, R. Girshick and A. Farhadi. You Only Look Once:Unified, Real-Time Object Detection. 2016 IEEE Conference on Computer Vision and Pattern Recognition. 2016:779-788.

13) Ronneberger O. FP, Brox T. U-Net:Convolutional Networks for Biomedical Image Segmentation. In:Navab N, Hornegger J, Wells W, Frangi A (eds) Medical Image Computing and Computer-Assisted Intervention - MICCAI 2015 MICCAI 2015 Lecture Notes in Computer Science, vol 9351 Springer, Cham. 2015.

14) Yamamoto Y, Saito A, Tateishi A, Shimojo H, Kanno H, Tsuchiya S, et al. Quantitative diagnosis of breast tumors by morphometric classification of microenvironmental myoepithelial cells using a machine learning approach. Sci Rep. 2017;7:46732.

15) Ian Goodfellow JP-A, Mehdi Mirza, Bing Xu, David Warde-Farley, Sherjil Ozair, Aaron Courville, Yoshua Ben-gio. Generative adversarial nets. Advances in neural information processing systems. 2014:2672-2680.

16) Silver D, Schrittwieser J, Simonyan K, Antonoglou I, Huang A, Guez A, et al. Mastering the game of Go without human knowledge. Nature. 2017;550(7676):354-359.

各論

P.325 掲載の参考文献

1) Cardiovascular Pathology 3rd ed. Churchill Livingstone Malcolm D. Silver et al.

2) Cardiovascular Pathology 4th ed. Elsevier/Academic Rress L. Maximilian Buja et al.

P.366 掲載の参考文献

1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会. 特発性間質性肺炎診断と治療の手引き(改訂第3版). 2016.

2) Travis WD, Colby TV, Koss MN, et al. Non-neoplastic disorders of the lower respiratory tract. In:Atlas of Nontumor Pathology, first series. Armed Forces Institute of Pathology;2002. p. 1-900.

3) Katzenstein A-L. Katzenstein and Askin's Surgical Pathology of Non-neoplastic Lung Disease. 4th ed. WB Saunders;2006. p.1-494.

4) 北村諭, 巽浩一郎, 石井芳樹. state of arts呼吸器疾患ver. 6. 別冊医学のあゆみ. 2013.

5) Beckett WS. Occupational respiratory diseases. N Engl J Med. 2000;342:406-413.

6) Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.

7) Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-280.

8) Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001;344:350-362.

9) Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517-525.

10) Fedullo PF, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465-1472.

11) Forastiere A, et al. Head and neck cancer. N Engl J Med. 2001;345:1890-1900.

12) Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383-1393.

13) Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527-2539.

14) Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.

15) Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.

16) Noguchi M. Stepwise progression of pulmonary adenocarcinoma. Clinical and molecular implications. Cancer Metastasis Rev. 2010;29:15-21.

17) Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29:633-639.

18) Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society International multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol. 2011;6:244-285.

19) 日本病理学会. ゲノム研究用・診療用病理組織検体取扱い規定. 羊土社, 2019.

20) Lancet Oncol. 2017 Apr;18(4):525-534.

21) Miret M, Horvath-Puho E, Deruaz-Luyet A, et al. PLoS One 2017;12:0181564.

22) Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracicmalignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47:1200-1205.

23) Chatzopoulos K, Boland JM. Update on geneticcally defined lung neoplasms:NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. Virchows Arch. 2021 Jan 6. doi:10.1007/s00428-020-03011-3. Online ahead of print.

24) Kubonishi I, Takehara N, Iwata J, et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res . 1991;51:3327-3328.

P.411 掲載の参考文献

1) Gross RE. Surgery of infancy and childhood. WB Saunders;1953.

2) Gillen P, et al. Experimental columnar metaplasia in the canine oesophagus. Br J Surg. 1988;75:113-115.

3) Boch JA, et al. Distribution of cytokeratin markers in Barrett's specialized columnar epithelium. Gastroenterol. 1997;112:760-765.

4) Tumours of the oesophagus. In:The WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours, Digestive System Tumours. IARC Press;2019. p.23-58.

5) がんの統計編集委員会(編). がんの統計<2019年版>. 財団法人がん研究振興財団;2019.

6) Oesophageal cancer. In:Wild CP, Weiderpass E and Stewart BW, editors. World Cancer Report. IARC Press;2020. p.323-232.

7) 日本食道学会(編). 臨床・病理食道癌取扱い規約(第11版). 金原出版, 2015.

8) Nakamura Y, et al. Multistep carcinogenesis of esophageal carcinoma. In:Tahara E, editor. Molecular Pathology of Gastroenterological Cancer. Springer Verlag;1997. p.15-21.

9) Huang PL, et al. Targeted disruption of the neuronal nitric oxide synthase gene. Cell. 1993;75:1273-1286.

10) Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273-1275.

11) Dixon MF, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161-1181.

12) Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4:688-694.

13) Furuta T, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92-105.

14) Hirayama F, et al. Induction of gastric ulcer and intestinal metaplasia in mongolian gerbils infected with Helicobacter pylori. J Gastroenterol. 1996;31:755-757.

15) Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature. 1990;343:82-85.

16) Wong WM, Playford RJ, Wright NA. Peptide gene expression in gastrointestinal mucosal ulceration:ordered sequence or redundancy? Gut. 2000;46:286-292.

17) Tumours of the stomach. In:Hamilton SR and Aaltonen LA, editors. World Health Organization Classification of Tumours, Pathology & Genetics Tumours of the Digestive System. IARC Press;2000. p.38-67.

18) Tumours of the stomach. In:The WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours, Digestive System Tumours IARC Press;2019. p.59-110.

19) Abraham SC, et al. Sporadic fundic gland polyps:common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158:1005-1010.

20) Stomach cancer. In:Wild CP, Weiderpass E and Stewart BW, editors. World Cancer Report. IARC Press;2020. p.333-343.

21) 日本胃癌学会(編). 胃癌取扱い規約(第15版). 金原出版;2017.

22) Lauren P. The two histological main types of gastric carcinoma:diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.

23) The Cancer Geneme Atlas Research Network. Complehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202-209.

24) 廣田誠一. GIST(gastrointestinal stromal tumor). 日本内科学会雑誌. 2004;93:1451-1458.

25) Asai N, et al. RET receptor signaling:dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int. 2006;56:164-172.

26) Green PHR, Cellier C. Celiac disease. N Engl J Med. 2007;357:1734-1743.

27) Abraham C and Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-2078.

28) Hugot J-P, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.

29) Danese S and Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713-1725.

30) Tumours of the colon and rectum. In:The WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours, Digestive System Tumours. IARC Press;2019. p. 157-192.

31) Colorectal cancer. In:Wild CPWeiderpass E and Stewart BW, editors. World Cancer Report. IARC Press;2020. p.344-354.

32) 大腸癌研究会(編), 大腸癌取扱い規約(第9版). 金原出版, 2018.

33) Sclemper RJ, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255.

34) Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36:2251-2270.

35) Vogelstein B, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.

36) Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170.

P.458 掲載の参考文献

1) Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Elsevier;2014.

1) Crawford JM, Burt AD. Anatomy, pathophysiology and basic mechanisms of disease. In:Burt AD, Portmann BC, Ferrell LD, editors. MacSween's Pathology of the Liver. 6th ed. UK:Churchill Livingstone Elsevier;2012. p.1-59.

2) 日本肝臓学会編. 慢性肝炎・肝硬変の診療ガイド2016. 文光堂;2016.

2) 急性胆管炎・胆嚢炎診療ガイドライン改訂出版委員会編. 急性胆管炎・胆嚢炎診療ガイドライン2013. 医学図書出版;2013.

3) Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4th ed. IARC Press;2010.

3) 日本肝臓学会編. NASH・NAFLDの診療ガイド2015. 文光堂;2015.

4) Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the gallbladder, extrahepatic bile ducts and vaterian system. AFIP Atlas of Tumor Pathology. 4th series. Fascicle 23. Armed Forces Institute of Pathlogy;2015.

4) Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261-1273.

5) Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. AFIP Atlas of Tumor Pathology. 4th series. Fascicle 6. Armed Forces Institute of Pathlogy;2007.

5) Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med. 2016;375:1161-1170.

6) Hay JE. Liver disease in pregnancy. Hepatology. 2008;47:1067-1076.

6) Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH:Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902-912.

7) Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4th ed. IARC Press;2010.

7) Basturk O, Hong SM, Wood LD, et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol. 2015;39:1730-1741.

8) 日本肝胆膵外科学会編. 臨床・病理胆道癌取扱い規約. 第6版. 金原出版;2013.

8) 日本肝癌研究会編. 臨床・病理原発性肝癌取扱い規約. 第6版. 金原出版;2015.

9) 日本膵臓学会編. 膵癌取扱い規約. 第7版. 金原出版;2016.

P.492 掲載の参考文献

1) Alpers CE, Chang A. The Kidney. In:Kumar V, et al, editors. Robbins and Cotran Pathologic Basis of Disease. 9th edition. Elsevier-Saunders;2015. p.897-957.

2) Cohen HT, McGovern FJ. Renal-call carcinoma. N Engl J Med. 2005;353:2477-2490.

3) George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-666.

4) Hudson BG, et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med. 2003;348:2543-2556.

5) Kwoh C, et al. Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol Mech Dis. 2006;1:349-374.

6) Mestecky J, et al. IgA nephropathy:Molecular mechanisms of the disease. Annu Rev Pathol Mech Dis. 2013;8:217-240.

7) Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394:1949-1964.

8) Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-A new look at an old entity. N Engl J Med. 2012;366:1119-1131.

9) Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151-164.

10) Wilson PD, Goilav B. Cystic disease of the kidney. Annu Rev Pathol Mech Dis. 2007;2:341-368.

P.504 掲載の参考文献

1) 日本泌尿器学会・日本病理学会・日本医学放射線学会, 編. 腎盂・尿管・膀胱癌取扱い規約. 第1版. 金原出版, 東京, 2011.

2) Cheng L, et al. Bladder cancer:translating molecular genetic insights into clinical practice. Hum Pathol. 2011;42:455-481.

3) Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 2013;31:398-406.

4) Cheng L, et al. Biomarkers in bladder cancer:translational and clinical implications. Crit Rev Oncol Hematol. 2014;89:73-111.

P.522 掲載の参考文献

1) 日本泌尿器学会・日本病理学会・日本医学放射線学会・編. 前立腺癌取扱い規約. 第4版. 金原出版;2010.

2) Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL;ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228-1242.

3) Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumoures of the urinary system and male genital organs. Chapter 3 tumoures of the prostate and 4 tumoures of the testis and paratesticular tissues. IARC Press;2016.

4) 日本泌尿器学会・日本病理学会・日本医学放射線学会・日本臨床腫瘍学会・編. 精巣腫瘍取扱い規約. 第4版. 金原出版;2018.

P.551 掲載の参考文献

1) WHO Classification of Tumours, 5th ed. Female Genital Tumours. (The WHO Classification of Tumours Editorial Board ed. ), IARC Press, Lyon, 2020.

2) 日本産婦人科学会・日本病理学会編. 子宮頸癌取扱い規約病理編. 第4版. 金原出版, 2017.

3) 日本産婦人科学会・日本病理学会編. 子宮頸癌取扱い規約臨床編. 第4版. 金原出版, 2020.

4) 日本産婦人科学会. 子宮頸がんとHPVワクチンに関する正しい理解のために. http://www.jsog.or.jp/modules/jsogpolicy/index.php?content_id=4

5) 婦人科腫瘍委員会報告. 2015年度患者年報. 日産婦誌. 2017;69:1171-1216.

6) 国立がん研究センターがん情報サービス http://ganjoho.jp/public/cancer/

7) 日本産婦人科学会・日本病理学会編. 子宮体癌取扱い規約病理編. 第4版. 金原出版, 2017.

8) 日本産婦人科学会・日本病理学会編. 卵巣腫瘍・卵管癌・腹膜癌取扱い規約病理編. 第1版. 金原出版, 2016.

9) Hartmann LC, et al. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374:454-68.

10) Karnezis, AN, Cho, KR, Gilks, CB et al. The disparate origins of ovarian cancers:pathogenesis and prevention strategies. Nat Rev Cancer. 2017, 17:65-74.

P.600 掲載の参考文献

1) 浅野茂隆, 池田康夫, 内山卓, 編. 三輪血液病学. 第3版. 文光堂;2006.

2) Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.

3) Ganz T. Anemia of inflammation. N Engl J Med. 2019;381:1148-1157.

4) Cines DB, Blanchette VS. Inmune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.

5) Chiorazzi N, Rai K, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804-815.

6) Pui C-H, Relling MV, Downig JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.

7) Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.

8) Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of B-cell lymphomas. N Engl J Med. 1999;341:1520-1529.

P.619 掲載の参考文献

1) D. E. Elder, R. Elenitsas, M. Rosenbach, et al. (eds. ) Lever's Histopathology of the Skin. 11th ed. WOLTERS KLUWER;2015.

2) Elder DE, Massi D, Scolyer RA, Willemze R. WHO Classification of Skin Tumors. IARC Press;2018.

3) Patterson JW, Wick MR. Nonmelanocytic tumors of the skin. In:AFIP Atlas of Tumor Pathology. Series 4. ARP Press;2006.

P.693 掲載の参考文献

1) Love S, et al, eds. Greenfield's Neuropathology. 9th ed. vol 1 & 2, Hodder Arnold;2015.

2) Esiri M, Perl D, eds. Oppenheimer's Diagnostic Neuropathology:A Practical Manual. 3rd ed. Hodder Arnold;2006.

3) Zlokovic BV. The blood brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178-201.

4) Kempermann G. The neurogenic reserve hypothesis:what is adult hippocampal neurogenesis good for? Trends Neurosci. 2008;31:163-169.

5) Skovronsky DM, et al. Neurodegenerative diseases:new concepts of pathogenesis and their therapeutic implications. Ann Rev Pathol Mech Dis . 2006;1:151-170.

6) Kwong LK, et al. TDP-43 proteinopathies:neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals . 2008;16:41-51.

7) Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Ann Rev Neurosci. 2007;30:575-621.

8) WHO Classification of Tumours of the Central Nervous System. IARC;2016.

9) 埜中征哉. 臨床のための筋病理. 第4版. 日本医事新報社;2011.

10) The Committee of Brain Tumor Resistry of Japan.:Neurologia medico-chirurgica 2017;Suppl;57.

11) Findlay AR et al. AN OVERVIEW OF POLYMYOSITIS AND DERMATOMYOSITIS. Muscle Nerve. 2015;51:638-656.

12) 鈴木重明. 抗合成酵素ミオパチー. 臨床神経. 2020;60:175-180.

P.709 掲載の参考文献

1) Standring S, Gray H. Gray's anatomy:the anatomical basis of clinical practice. 40th ed. Edinburgh:Churchill Livingstone/Elsevier;2008. p.928-938.

2) Neville MC, Neifert MR. Lactation:physiology, nutrition, and breast-feeding. New York:Plenum Press;1983.

3) Research. WCRFaAIfC. Food, nutrition, physical activity and the prevention of cancer:a Global perspective. Washington DC:Am Insti Cancer Res;2007.

4) Gaben AM, et al. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase. Mol Endocrinol. 2004;18:2700-2713.

5) Sabbah M, et al. Estrogen induction of the cyclin D1 promoter:involvement of a cAMP response-like element. PNAS. 1999;96:11217-11222.

6) Kimberly A et al. Breast Tumours, WHO Classification of Tumours Editorial Board;WHO Classification of Tumours 5th ed. World Health Organization, 2018.

7) Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history:a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.

8) Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-1333.

9) Robbins SL, Kumar V, Cotran RS. Robbins and Cotran pathologic basis of disease. 8th ed. Philadelphia:Saunders/Elsevier;2010. p.1065-1095.

10) 日本乳癌学会編. 乳癌取り扱い規約. 第17版. 東京:金原出版;2012.

11) Tognon C, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367-376.

12) Wetterskog D, et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 2012;226:84-96.

13) Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.

14) Weigelt B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-150.

15) Foulkes WD, Smith IE, Reis-Filho JS. Triplenegative breast cancer. N Engl J Med. 2010;363:1938-1948.

P.721 掲載の参考文献

1) Williams Textbook of Endocrinology, Section II:Hypothalamus and Pituitary. 13th ed. Elsevier;2016.

2) Robbins and Cotran Pathologic Basis of Disease, Chapter 24, Endocrine system (Pituitary gland). 19th ed. Elsevier;2014.

3) Asa SL, Ezzat S. Pathogenesis of pituitary tumors. Annu Rev Pathol. 2009;4:97-126.

4) Lynn Loriaux D. Diagnosis and Differential Diagnosis of Cushing's Syndrome. N Engl J Med . 2017;376:1451-1459.

5) Harvinder S. Chaha, et al. AIP Mutation in Pituitary Adenomas in the 18th Century and Today. N Engl J Med. 2011;364:43-50.

6) 臨床・病理. 脳腫瘍取り扱い規約. 第4版. 金原出版;2018.

7) 外科病理学. 第5版. 文光堂;2020.

P.740 掲載の参考文献

1) Braverman LE, et al, eds. Werner & Ingbar's The Thyroid. 11th ed. Wolters Kluwer;2020.

2) John EH. Guyton and Hall. Textbook of Medical Physiology. Chapter 77, Thyroid metabolic hormones. 13th ed. Elsevier;2016.

3) Kumar V, et al, eds. Robbins & Cotran. Chapter 24, Endocrine system (thyroid gland). 10th ed. Elsevier;2020.

4) Nikiforov, YE, et al, eds. Diagnostic Pathology and Molecular Genetics of the thyroid. 3rd, eds. Wolters Kluwer;2018.

5) Lloyd RV, et al, eds. WHO classification of Tumours of endocrine. Chapter 2, Tumours of the thyroid gland. IARC;2017.

6) Ali SZ, et al, eds. The Bethesda System for Reporting Thyroid Cytopathology:Definitions, Criteria, and Explanatory Notes. 2nd, eds. Springer 2017.

P.743 掲載の参考文献

1) John EH. Guyton and Hall. Textbook of Medical Physiology. Chapter 80, Parathyroid Hormone, Calcitonin, Calcium and Phosphate Metabolism, Vitamin D, Bone, and Teeth. 13th ed. Elsevier;2016.

2) Kumar V, et al, eds. Robbins & Cotran. Chapter 24, Endocrine system (parathyroid glands). 10th ed. Elsevier;2020.

3) Lloyd RV, et al, eds. WHO classification of Tumours of endocrine. Chapter 3, Tumours of the parathyroid glands, and Chapter 7, Inherited tumors syndromes. IARC;2017.

P.754 掲載の参考文献

1) Williams Textbook of Endocrinology, Section IV:Adrenal Cortex and Endocrine Hypertension. 13th ed. Elsevier;2016.

2) Robbins and Cotran Pathologic Basis of Disease, Chapter 24, Endocrine system (Adrenal gland). 19th ed. Elsevier;2014.

3) El-Maouche D, et al. Congenital adrenal hyperplasia. Lancet. 2017;390:2194-2210.

4) Lacroix A, et al. Cushing's syndrome. Lancet. 2015;386:913-927.

5) Louiset E, et al. Intraadrenal Corticotropin in Bilateral Macronodular Adrenal Hyperplasia. N Engl J Med. 2013;369:2115-2125.

6) 副腎腫瘍取扱い規約. 第3版. 金原出版;2015.

7) WHO Classification of Tumours of Endocrine Organs, 4th ed. 2017.

8) 腫瘍病理鑑別診断アトラス. NET・下垂体・副甲状腺・副腎. 文光堂;2017.

9) 内分泌腫瘍. 甲状腺・副腎(癌診療指針のための病理診断プラクティス). 中山書店;2018.

10) 副腎の病理. 病理と臨床33巻12号. 文光堂;2015.

11) Yamazaki Y, et al. J Clin Endocrinol Metab. 2017;102:1182-1192.

12) 副腎ホルモン産生異常に関する調査研究. (http://www.pediatric-world.com/fukujin/index.html)

P.762 掲載の参考文献

1) Robinson BWS, Lake R. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.

2) Aozasa K, et al. Pyothorax-associated lymphoma-a lymphoma developing in chronic inflammation. Adv Anat Pathol. 2005;12:324-331.

P.770 掲載の参考文献

1) Hsu CR, Chen YY, Yao M, Wei YH, Hsieh YT, Lio SL. Orbital and ocular adnexal lymphoma:a review of epidemiology and prognostic factors in Taiwan. Eye (Lond). 2021 Jul;35(7):1946-1953. doi:10.1038/s41433-020-01198-y. Epub2020 Sep 29.

2) Kumar S, Malik MA, Goswami S, Shihota R, Kaur J. Candidate genes involved in the susceptibility of primary open angle glaucoma. Gene. 2016 Feb 15;577(2):119-31. doi:10.1016/j. gene. 2015.11.032. Epub 2015 Nov 24. PMID:26621382 Review.

P.806 掲載の参考文献

1) WHO Classifications of Tumours, 5th Edition. Soft Tissue and Bone Tumours. IARC Lyon;2020.

2) 石田剛, 今村哲夫. 非腫瘍性骨関節疾患の病理. 文光堂;2002.

3) 岩本幸英編. 神中整形外科学. 改訂第23版. 南山堂, 2013.

4) Goldblum JR, Folpe AL, Weiss SW. Enzinger & Weiss's Soft Tissue Tumors 6th Edition. Mosby Elsevier;2014.

5) Unni KK, Inwards CY. Dahlin's Bone Tumors. 7th Edition. Lippincott Williams & Wilkins;2020.

6) 井樋栄二, 吉川秀樹, 津村弘, 田中栄, 高木理彰編. 標準整形外科学. 第14版. 医学書院, 2014.

7) 大塚隆信, 福田国彦, 小田義直編. 骨・軟部腫瘍:臨床・画像・病理. 第2版. 診断と治療社, 2015.

P.825 掲載の参考文献

1) Soames JV, Southam JC. Oral Pathology. 4th ed. Oxford University Press;2005.

2) Regezi JA, et al. Oral Pathology, Clinical Pathologic Correlations. 7th ed. Saunders;2017.

3) Neville BW, et al. Oral and Maxillofacial Pathology. 4th ed. WB Saunders;2016.

4) El-Naggar AK, et al, editors. WHO Classification of Head and Neck Tumours. IARC Press;2017.

5) 特定非営利活動法人・日本歯周病学会編. 歯周病の診断と治療の指針2007. 日本歯周病学会;2007:1-8.

6) Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions:an overview of the literature. J Oral Pathol Med. 2008;37:1-10.

7) Brennan JA, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:712-717.

8) Shear M, Speight PM. Cysts of the oral and maxillofacial regions. 4th ed. Blackwell Munksgaard;2007.

9) Stenman G. Fusion oncogenes and tumor type specificity--insights from salivary gland tumors. Semin Cancer Biol. 2005;15:224-235.

書評

書評を投稿する

最近チェックした商品履歴

Loading...